Claims for Patent: 6,632,456

Summary for Patent: 6,632,456

Title:	Compositions for inhalation
Abstract:	A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.
Inventor(s):	Backstrom; Kjell Goran Erik (Lund, SE), Dahlback; Carl Magnus Olof (Lund, SE), Edman; Peter (Bjarred, SE), Johansson; Ann Charlotte Birgit (Lund, SE)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	08/960,093
Patent Claims:	1. A composition consisting essentially of (A) a polypeptide, (B) one or more substances which enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said composition being in the form of a dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of up to about 10 microns, provided that each of said one or more substances is selected from the group consisting of a C.sub.8 -C.sub.16 fatty acid, a salt of said fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, and an alkyl saccharide. 2. The composition of claim 1, wherein the composition contains only (A) and (B). 3. The composition of claim 1, wherein the composition contains a non-hygroscopic additive which is a pharmaceutically acceptable carrier. 4. The composition of claim 1, wherein at least one of said one or more substances is selected from the group consisting of sodium, potassium and lysine salts of caprylic acid (C.sub.8), capric acid (C.sub.10), lauric acid (C.sub.12), and myristic acid (C.sub.14). 5. The composition of claim 1, wherein at least one of said one or more substances is selected from the group consisting of an alkyl glucoside and alkyl maltoside. 6. The composition of claim 1, wherein at least one of said one or more substances is selected from the group consisting of a decyl glucoside, dodecyl glucoside, decyl maltoside, and dodecyl maltoside. 7. The composition of claim 1, wherein at least one of said one or more substances is selected from the group consisting of sodium and potassium salts of glycyrrhizine acid. 8. The composition of claim 1, wherein at least one of said one or more substances is selected from the group consisting of decanoyl carnitine, lauryl carnitine, myristoyl carnitine, and palmitoyl carnitine. 9. The composition of claim 1, in which at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of between 1 and 6 microns. 10. The composition of claim 1, wherein the ratio of (A) to (B) is in the range of 9:1 to 1:1. 11. The composition of claim 1, wherein said polypeptide is a polypeptide hormone. 12. The composition of claim 1, wherein said polypeptide is selected from the group consisting of vasopressin, a vasopressin polypeptide analog, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, somatostatin, a somatostatin polypeptide analog, gonadotropin agonist, a gonadotropin agonist polypeptide analog, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, and prolactin. 13. The composition of claim 1, wherein said polypeptide is selected from the group consisting of a growth factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade. 14. The composition of claim 1, wherein said polypeptide has a molecular weight of less than 30 kD. 15. The composition of claim 1, wherein said polypeptide has a molecular weight of less than 15 kD. 16. A composition consisting essentially of (A) a polypeptide, (B) one or more phospholipids that enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said composition being in the form of a dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of up to about 10 microns. 17. The composition of claim 16, wherein the composition contains only said polypeptide and said one or more phospholipids. 18. The composition of claim 16, wherein the composition contains a non-hygroscopic additive which is a pharmaceutically acceptable carrier. 19. The composition of claim 16, wherein at least one of said one or more phospholipids is selected from the group consisting of diacylphosphatidylcholine, diacylphosphatidylglycerol, diacylphosphatidylethanolamine, diacylphosphatidylinositol, and diacylphosphatidylserine. 20. The composition of claim 16, wherein at least one of said one or more phospholipids is dioctanoylphosphatidylglycerol or dioctanoylphosphatidylcholine. 21. The composition of claim 16, in which at least 50% of the total mass of said polypeptide and said one or more phospholipids consists of primary particles having a diameter of between 1 and 6 microns. 22. The composition of claim 16, wherein the ratio of (A) to (B) is in the range of 9:1 to 1:1. 23. The composition of claim 16, wherein said polypeptide is a polypeptide hormone. 24. The composition of claim 16, wherein said polypeptide is selected from the group consisting of vasopressin, a vasopressin polypeptide analog, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, somatostatin, a somatostatin polypeptide analog, gonadotropin agonist, a gonadotropin agonist polypeptide analog, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, and prolactin. 25. The composition of claim 16, wherein said polypeptide is selected from the group consisting of a growth factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade. 26. The composition of claim 16, wherein said polypeptide has a molecular weight of less than 30 kD. 27. The composition of claim 16, wherein said polypeptide has a molecular weight of less than 15 kD. 28. The composition of claim 16, wherein at least one of said one or more phospholipids is a single-chain phospholipid. 29. The composition of claim 28, wherein at least one of said one or more phospholipids is selected from the group consisting of lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine. 30. The composition of claim 28, wherein at least one of said one or more phospholipids is palmitoylphosphatidylglycerol or palmitoylphosphatidylcholine. 31. The composition of claim 28, wherein the composition contains only (A) and (B). 32. The composition of claim 28, wherein the composition contains a non-hygroscopic additive which is a pharmaceutically acceptable carrier. 33. The composition of claim 28, in which at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of between 1 and 6 microns. 34. The composition of claim 28, wherein the ratio of (A) to (B) is in the range of 9:1 to 1:1. 35. The composition of claim 28, wherein said polypeptide is a polypeptide hormone. 36. The composition of claim 28, wherein said polypeptide is selected from the group consisting of vasopressin, a vasopressin polypeptide analog, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, somatostatin, a somatostatin polypeptide analog, gonadotropin agonist, a gonadotropin agonist polypeptide analog, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, and prolactin. 37. The composition of claim 28, wherein said polypeptide is selected from the group consisting of a growth factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade. 38. The composition of claim 28, wherein said polypeptide has a molecular weight of less than 30 kD. 39. The composition of claim 28, wherein said polypeptide has a molecular weight of less than 15 kD. 40. The composition of claim 1, wherein the composition includes (C). 41. The composition of claim 1, wherein the primary particles are agglomerated. 42. The composition of claim 16, wherein the composition includes (C). 43. The composition of claim 16, wherein the primary particles are agglomerated.

Details for Patent 6,632,456

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-06-23